Neurotrope Inc. | Mutual Funds
Mutual Funds that own Neurotrope Inc.
Vanguard Total Stock Market Index Fund
131,201
1.66%
0
0%
07/31/2018
Vanguard Extended Market Index Fund
67,260
0.85%
0
0%
07/31/2018
Tanaka Growth Fund
43,300
0.55%
2,450
2.99%
05/31/2018
iShares Micro Cap ETF
19,936
0.25%
0
0.02%
09/06/2018
DFA US Micro Cap Portfolio
13,137
0.17%
0
0%
04/30/2018
DFA US Small Cap Portfolio
12,308
0.16%
0
0%
04/30/2018
AlphaNorth Growth Fund
12,000
0.15%
0
4.28%
12/31/2017
Vanguard Institutional Total Stock Market Index Fund
11,123
0.14%
0
0%
07/31/2018
DFA US Targeted Value Portfolio
3,058
0.04%
0
0%
04/30/2018
Vanguard Balanced Index Fund
3,042
0.04%
0
0%
07/31/2018
| Address |
205 East 42nd Street
New York New York 10017
United States
|
|
Employees
|
- |
| Website |
http://www.neurotropebioscience.com |
| Updated |
07/08/2019 |
| Neurotrope, Inc. is a biopharmaceutical company, which engages in the pre-clinical and clinical development of its product candidates. It operates through the following geographical segments: US; European Union; Japan; and China and India. It focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. |
